CEO Andrew Oxtoby was paid $2,569,115 in fiscal year 2025: executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Buy the report for KLRS
The free brief above is the whole reading. Each report is the same data as a presentation-ready document, generated for this company at the moment of purchase.
Order KLRS
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
This is the complete answer, not a partial one — the list is never padded.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Andrew Oxtoby | $537,733 | $0 | $0 | $1,687,076 | $344,306 | $0 | $0 | $2,569,115 |
| President and Chief Executive Officer | ||||||||
| Matthew Feinsod | 457,732 | 0 | 0 | 1,008,403 | 207,636 | 0 | 0 | 1,673,771 |
| Chief Medical Officer | ||||||||
| Brett Hagen | 397,301 | 67,814 | 0 | 295,417 | 121,512 | 0 | 557,130 | 1,439,174 |
| Chief Accounting Officer and AlloVir’s former Chief Accounting Officer | ||||||||
| Vikas Sinha | 81,106 | 0 | 0 | 0 | 0 | 0 | 1,019,848 | 1,100,954 |
| AlloVir’s Former Chief Executive Officer, President and Chief Financial Officer | ||||||||
| Matthew Gall | 80,833 | 0 | 0 | 949,279 | 34,495 | 0 | 0 | 1,064,607 |
| Former Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Andrew Oxtoby | $2,569,115 | $1,965,153 | — | +603,962 |
| Matthew Feinsod | 1,673,771 | — | — | — |
| Brett Hagen | 1,439,174 | 796,311 | — | +642,863 |
| Vikas Sinha | 1,100,954 | 544,400 | — | +556,554 |
| Matthew Gall | 1,064,607 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Matthew Gall | Option | 235,000 | 4.99 | — |
| Matthew Feinsod | Option | 52,913 | 7.31 | — |
| Andrew Oxtoby | Option | 268,090 | 0.85 | — |
| Andrew Oxtoby | Option | 287,000 | 7.31 | — |
| Matthew Feinsod | Option | 20,160 | 0.85 | — |
| Matthew Feinsod | Option | 101,000 | 7.31 | — |
| Brett Hagen | Option | 50,262 | 7.31 | — |
The company's compensation program is designed to attract, motivate, and retain executive officers by rewarding the achievement of near-term and longer-term financial and strategic goals. The board strives to provide a mix of short-term and long-term performance-based incentives to align executive interests with stockholders and drive corporate performance without encouraging excessive risk-taking.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon plc |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| David HallalIndependent · Board Chair · Compensation | $140,000 | — | $104,430 | — | $0 | $244,430 |
| Morana Jovan-Embiricos, Ph.DIndependent | 51,875 | — | 104,430 | — | 0 | 156,305 |
| Napoleone Ferrara, M.DIndependent | 33,000 | — | 104,430 | — | 13,663 | 151,093 |
| Leone PattersonIndependent · Audit (Chair) · Newly elected | 41,250 | — | 104,430 | — | 0 | 145,680 |
| Michael Dybbs, Ph.DIndependent | 39,000 | — | 104,430 | — | 0 | 143,430 |
| Anthony P. Adamis, M.DIndependent · Audit | 35,625 | — | 104,430 | — | 1,850 | 141,905 |
| Srinivas Akkaraju, M.D., Ph.DNot independent | 36,000 | — | 104,430 | — | 0 | 140,430 |
| Jeffrey S. BornsteinNot independent · Not standing for re-election · Departed during FY | 16,875 | — | 0 | — | 0 | 16,875 |
| Shawn TomaselloNot independent · Not standing for re-election · Departed during FY | 13,750 | — | 0 | — | 0 | 13,750 |
| Derek Adams, Ph.DIndependent | 13,125 | — | 0 | — | 0 | 13,125 |
| Malcolm Brenner, M.D., Ph.DNot independent · Not standing for re-election · Departed during FY | 12,500 | — | 0 | — | 0 | 12,500 |
| Juan Vera, M.DNot independent · Not standing for re-election · Departed during FY | 10,000 | — | 0 | — | 0 | 10,000 |
| Andrew OxtobyEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 6,000 / 4,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $443,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $15,513 |
| Total cost of the board | $458,513 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Kalaris Therapeutics, Inc. | 2025 | Andrew Oxtoby | $537,733 | $0 | $1,687,076 | $344,306 | $2,569,115 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Andrew Oxtoby | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Summary Compensation Table”. As printed: 2,569,115. Filing ↗machine: r2 · c27 · span 295176–295185 |
| 2 | Section 01, Matthew Feinsod | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Summary Compensation Table”. As printed: 1,673,771. Filing ↗machine: r5 · c27 · span 301661–301670 |
| 3 | Section 01, Brett Hagen | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Summary Compensation Table”. As printed: 1,439,174. Filing ↗machine: span 312546–312555 |
| 4 | Section 01, Vikas Sinha | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Summary Compensation Table”. As printed: 1,100,954. Filing ↗machine: r8 · c26 · span 307794–307803 |
| 5 | Section 01, Matthew Gall | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Summary Compensation Table”. As printed: 1,064,607. Filing ↗machine: span 305646–305655 |
| 6 | Section 08, David Hallal | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 244,430. Filing ↗machine: span 406054–406193 |
| 7 | Section 08, Morana Jovan-Embiricos, Ph.D | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 156,305. Filing ↗machine: span 408829–408968 |
| 8 | Section 08, Napoleone Ferrara, M.D | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 151,093. Filing ↗machine: span 425364–425503 |
| 9 | Section 08, Leone Patterson | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 145,680. Filing ↗machine: span 430873–431012 |
| 10 | Section 08, Michael Dybbs, Ph.D | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 143,430. Filing ↗machine: span 422600–422739 |
| 11 | Section 08, Anthony P. Adamis, M.D | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 141,905. Filing ↗machine: span 417083–417222 |
| 12 | Section 08, Srinivas Akkaraju, M.D., Ph.D | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 140,430. Filing ↗machine: span 419859–419998 |
| 13 | Section 08, Jeffrey S. Bornstein | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 16,875. Filing ↗machine: span 398701–398839 |
| 14 | Section 08, Shawn Tomasello | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 13,750. Filing ↗machine: span 409738–409876 |
| 15 | Section 08, Derek Adams, Ph.D | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 13,125. Filing ↗machine: span 395951–396089 |
| 16 | Section 08, Malcolm Brenner, M.D., Ph.D | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 12,500. Filing ↗machine: span 401484–401622 |
| 17 | Section 08, Juan Vera, M.D | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 10,000. Filing ↗machine: span 412509–412647 |
| 18 | Section 08, Andrew Oxtoby | DEF 14A | 2026-04-24 | 0001193125-26-177362 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 19 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 20 | Section 09b board cost (computed) | Computed | — | — | Cash 443,000 + equity 0 + all other 15,513 = 458,513, summed across the director compensation table rows.machine: formula: Σ = 458,513 |
| 21 | Kalaris Therapeutics, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177362 | CEO total compensation as printed in Kalaris Therapeutics, Inc.'s own proxy. As printed: 2,569,115. Filing ↗machine: r2 · c27 · span 295176–295185 |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat